Kronos Bio Appoints Industry Veteran, Jennifer Nicholson, M.H.A., as Vice President, Regulatory Affairs

SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., dedicated to targeting oncogenic transcription factors and associated transcriptional regulatory networks, today announced the appointment of Jennifer Nicholson, M.H.A., to the newly created position of Vice President, Regulatory Affairs. Ms. Nicholson joins the company with nearly 20 years of experience in regulatory affairs, with a focus on oncology across all stages of development. In this role, she will be responsible for leading the company’s regulatory function and will oversee various regulatory submissions and global regulatory strategy.

“Jennifer’s deep experience in regulatory affairs in the biopharma industry, and her proven track record of building relationships with U.S. and global regulatory authorities and successfully completing major regulatory submissions, brings critical expertise to our Senior Management team,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “As we continue to advance our growing preclinical-stage pipeline we are very pleased to welcome Jennifer to Kronos Bio and look forward to her contributions.”

Prior to joining Kronos, Ms. Nicholson served as Head of Regulatory at Acerta Pharma, a member of the AstraZeneca Group. As Global Regulatory Lead for Calquence (acalabrutinib), she led the New Drug Application (NDA) submission for relapsed/refractory mantle cell lymphoma as well as subsequent submissions for other indications. Prior to joining Acerta, she was Senior Director, Regulatory Affairs, at Bavarian Nordic, focusing on cancer immunotherapy treatments. Earlier in her career, she was the Global Regulatory Lead for various hematology and oncology treatments at Jazz Pharmaceuticals and Onyx Pharmaceuticals. She began her career in regulatory affairs at Genentech, where she worked for 11 years, holding positions of increasing responsibility.

“I have been closely following Kronos Bio and am excited about the rapid progress the company has made in pursuing oncology targets that have been considered undruggable using its innovative screening platform and technology,” said Ms. Nicholson. “At this transformative time for Kronos I am excited to work with the incredible management team and put my two decades of regulatory experience to work.”

Ms. Nicholson received a B.S. in biochemistry and cell biology from the University of California, San Diego, and a Master of Healthcare Administration (M.H.A.) from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.

About Kronos Bio

Kronos Bio is a biopharmaceutical company that seeks to transform patient outcomes by targeting the oncogenic transcription factors and their associated transcriptional regulatory networks (“TRNs”) that define the cancer phenotype. We leverage deep capabilities in systems biology, chemical biology and clinical translational expertise in order to map these oncogenic TRNs, screen for small molecule modulators and identify selective vulnerabilities.

For more information, please visit www.kronosbio.com or follow the company on LinkedIn.